Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:605033'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.62 Med: 17.95 Max: 35.26
Current: 6.06
During the past 9 years, Shaanxi Meibang Pharmaceutical Group Co's highest Return-on-Tangible-Equity was 35.26%. The lowest was 3.62%. And the median was 17.95%.
SHSE:605033's Return-on-Tangible-Equity is ranked worse than 54.22% of 249
companies
in the Agriculture industry
Industry Median: 7.18
vs SHSE:605033: 6.06
Shaanxi Meibang Pharmaceutical Group Co (SHSE:605033) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Shaanxi Meibang Pharmaceutical Group Co Return-on-Tangible-Equity Related Terms
Shaanxi Meibang Pharmaceutical Group Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shaanxi Meibang Pharmaceutical Group Co Return-on-Tangible-Equity Chart
Shaanxi Meibang Pharmaceutical Group Co Annual Data
SHSE:605033 vs CTVA, CF, MOS: Return-on-Tangible-Equity Comparison
For the Agricultural Inputs subindustry, Shaanxi Meibang Pharmaceutical Group Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shaanxi Meibang Pharmaceutical Group Co Return-on-Tangible-Equity vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Shaanxi Meibang Pharmaceutical Group Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Shaanxi Meibang Pharmaceutical Group Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.75% mean?
Shaanxi Meibang Pharmaceutical Group Co (SHSE:605033) has a Return-on-Tangible-Equity of 5.75% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shaanxi Meibang Pharmaceutical Group Co and its competitors. This is 68% below median its historical median of 17.95. Over the past decade, Shaanxi Meibang Pharmaceutical Group Co's Return-on-Tangible-Equity has ranged from 3.62 to 35.26. According to the industry distribution chart, Shaanxi Meibang Pharmaceutical Group Co ranks #135 out of 249 companies in the Agriculture industry, placing it in the top 54.2%.
Is Shaanxi Meibang Pharmaceutical Group Co's Return-on-Tangible-Equity too high?
Shaanxi Meibang Pharmaceutical Group Co's current Return-on-Tangible-Equity of 5.75% is 68% below median its 10-year median of 17.95. Over the past 10 years, this metric has ranged from a low of 3.62 to a high of 35.26. The Agriculture industry median Return-on-Tangible-Equity is 7.18. Shaanxi Meibang Pharmaceutical Group Co's value of 5.75% is 19.9% below this industry median. Based on the distribution chart, Shaanxi Meibang Pharmaceutical Group Co ranks #135 out of 249 companies in the Agriculture industry, which is below the industry midpoint. Overall, Shaanxi Meibang Pharmaceutical Group Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shaanxi Meibang Pharmaceutical Group Co's Return-on-Tangible-Equity compare to CTVA and CF?
According to the Agriculture industry distribution chart, Shaanxi Meibang Pharmaceutical Group Co ranks #135 out of 249 companies for Return-on-Tangible-Equity. This places Shaanxi Meibang Pharmaceutical Group Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.18. Shaanxi Meibang Pharmaceutical Group Co's value of 5.75% is 19.9% below this benchmark. Historically, Shaanxi Meibang Pharmaceutical Group Co's own Return-on-Tangible-Equity has ranged from 3.62 to 35.26 over the past decade. While the company's 10-year median is 17.95 vs. the industry median of 7.18, Shaanxi Meibang Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for an Agriculture company?
The median Return-on-Tangible-Equity among Agriculture companies is 7.18, based on 249 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shaanxi Meibang Pharmaceutical Group Co's current Return-on-Tangible-Equity of 5.75% is 19.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shaanxi Meibang Pharmaceutical Group Co and its competitors. For the Agriculture industry, the median Return-on-Tangible-Equity is 7.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shaanxi Meibang Pharmaceutical Group Co's current Return-on-Tangible-Equity is 5.75%, which is 68% below median its own 10-year median of 17.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shaanxi Meibang Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Shaanxi Meibang Pharmaceutical Group Co (SHSE:605033) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥22.19, compared to a current price of ¥18.22 — trading 17.9% below its estimated fair value. The current Return-on-Tangible-Equity is 5.75%, which is 68% below median its 10-year median of 17.95 and 19.9% below the Agriculture industry median of 7.18. Shaanxi Meibang Pharmaceutical Group Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Shaanxi Meibang Pharmaceutical Group Co (SHSE:605033), the current Return-on-Tangible-Equity is 5.75% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shaanxi Meibang Pharmaceutical Group Co (SHSE:605033) Overvalued in 2026?
Based on GuruFocus' analysis, Shaanxi Meibang Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥18.22 is trading 17.9% below its estimated GF Value™ of ¥22.19.
GuruFocus considers Shaanxi Meibang Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:605033:
Return-on-Tangible-Equity: 5.75% (68% below median its 10-year median of 17.95)
GF Value™: ¥22.19 vs. price of ¥18.22 (17.9% below fair value)
Industry Position: 19.9% below the Agriculture median (#135 of 249)
No single metric tells the full story. See the SHSE:605033 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605033 has been successfully added to your 
